You are here: Industry Insights > Merck KGaA

News List

Merck KGaA taps Cyclica for AI-based screening of protein-drug interactions fiercebiotech
December 28, 2018
Merck KGaA has licensed a cloud-based artificial intelligence proteome screening platform from the Toronto-based Cyclica.The yearlong agreement will allow the German biotech to evaluate the mechanisms of action and...
Merck KGaA hands over CAR-T therapy business to Intrexon in deal worth $175 million pharmafile
December 24, 2018
German pharma firm Merck KGaA has agreed to hand over its CAR-T therapy business to US company Intrexon in a deal worth $175 million.
Merck KGaA, Darmstadt, Germany Announces Orphan Drug Designation for M7824 americanpharmaceuticalreview
December 12, 2018
Merck KGaA, Darmstadt, Germany announced the US Food and Drug Administration (FDA) has granted orphan drug designation (ODD) to M7824, the first regulatory designation.....
Merck KGaA links with AI firm to iron out side-effects during R&D pharmaphorum
December 11, 2018
Germany’s Merck KGaA has begun a licensing agreement with Canadian pharma R&D company Cyclica using artificial intelligence (AI) to uncover new drug targets and predict any side effects.
Merck KGaA, GlucoMe to pilot remote, digital diabetes care in Vietnam fiercebiotech
August 27, 2018
Merck KGaA has tapped digital diabetes platform provider GlucoMe for a pilot collaboration in several hospitals across Vietnam, comparing its system to the current standard of care in the country with the fastest-growing rate of the disease in Southeast A
Vyriad Announces Collaboration with Merck KGaA and Pfizer to Evaluate Voyager-V1, Avelumab americanpharmaceuticalreview
July 24, 2018
Vyriad has announced a collaboration agreement with Merck KGaA, Darmstadt, Germany, and Pfizer to expand its ongoing Phase 1 clinical trial program in solid tumors to include a combination study of its lead asset, Voyager-V1, with avelumab, a human anti-P
Mylan Rumored to be in Discussions to Buy Merck KGaA’s Consumer Health Business, but Mylan Denies It biospace
April 16, 2018
Canonsburg, Pennsylvania-based Mylan is reportedly in top-level talks with Germany’s Merck KGaA to buy its consumer health business. However, Mylan has denied it.
Merck KGaA Looks to Sell Consumer Health Biz contractpharma
September 07, 2017
Merck KGaA of Darmstadt, Germany, is looking at strategic options for the potential sale of its Consumer Health business.
After 7 years, EC grants approval for Merck KGaA’s MS drug pharmafile
August 28, 2017
Pharmacovigilance is a science of understanding drug safety through identification, assessment, and prevention of adverse drug reactions (ADRs).
Lawmakers dig into 'skyrocketing' MS costs with probe into 7 drugmakers fiercepharma
August 18, 2017
Rep. Elijah Cummings, along with Rep. Peter Welch, announced a probe into MS drug costs

Previous page 1 2 3 4 Next page